CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company
focused on creating transformative gene-based medicines for serious
diseases, today announced that members of its senior management
team are scheduled to participate in the following virtual investor
conferences in March:
Barclays Global Healthcare
ConferenceDate: Tuesday, March 9, 2021Time: 10:20 a.m.
Annual Roth ConferenceDate: Monday, March 15,
2021Time: 1:30 p.m. ET
A live webcast of these events will be available
on the "Events & Presentations" page in the Investors section
of the Company's website at https://crisprtx.gcs-web.com/events. A
replay of the webcasts will be archived on the Company's website
for 14 days following each presentation.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing
company focused on developing transformative gene-based medicines
for serious diseases using its proprietary CRISPR/Cas9 platform.
CRISPR/Cas9 is a revolutionary gene editing technology that allows
for precise, directed changes to genomic DNA. CRISPR Therapeutics
has established a portfolio of therapeutic programs across a broad
range of disease areas including hemoglobinopathies, oncology,
regenerative medicine and rare diseases. To accelerate and expand
its efforts, CRISPR Therapeutics has established strategic
collaborations with leading companies including Bayer, Vertex
Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is
headquartered in Zug, Switzerland, with its wholly-owned U.S.
subsidiary, CRISPR Therapeutics, Inc., and R&D operations based
in Cambridge, Massachusetts, and business offices in San Francisco,
California and London, United Kingdom. For more information, please
CRISPR THERAPEUTICS® word mark and design logo
are trademarks and registered trademarks of CRISPR Therapeutics AG.
All other trademarks and registered trademarks are the property of
their respective owners.
Media Contact:Rachel Eides WCG on behalf of